United-Guardian, Inc.  

(Public, NASDAQ:UG)   Watch this stock  
Find more results for UG
-0.06 (-0.32%)
Real-time:   12:56PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 18.58 - 19.88
52 week 18.58 - 35.25
Open 19.88
Vol / Avg. 4,835.00/4,307.00
Mkt cap 82.85M
P/E 19.89
Div/yield 0.32/4.23
EPS 0.95
Shares 4.60M
Beta -0.02
Inst. own 18%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 16.35% 38.29%
Operating margin 21.61% 54.30%
EBITD margin - 48.59%
Return on average assets 10.38% 40.01%
Return on average equity 11.30% 43.61%
Employees 33 -
CDP Score - -


230 Marcus Blvd.
United States - Map
+1-631-2730900 (Phone)
+1-631-2730858 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


United-Guardian, Inc. is an integrated research, development, manufacturing, and marketing company. The Company supply products to the personal care, health care, industrial, and pharmaceutical sectors. The company's products are developed and manufactured by its Guardian Laboratories Division. The personal care and cosmetic ingredients are marketed through a worldwide network of marketing partners and distributors. The pharmaceuticals are sold to full-line drug wholesalers, which distribute them to pharmacies, hospitals, physicians, long-term care facilities, and other health care providers. The health care products are marketed to manufacturers of medical devices and other medical products, which incorporate them into their finished products and distribute them to hospitals, pharmacies, and other health care facilities. The Company�s two major product lines, Lubrajel and Renacidin Irrigation (Renacidin) together accounted for 94.4% of revenue as of December 31, 2013.

Officers and directors

Kenneth H. Globus Chairman of the Board, President, General Counsel
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert S. Rubinger Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director
Age: 71
Bio & Compensation  - Reuters
Peter A. Hiltunen Vice President
Age: 55
Bio & Compensation  - Reuters
Joseph J. Vernice Vice President, Manager - Research and Development, Director - Technical Services
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Roseann LaCorte Controller
Age: 47
Bio & Compensation  - Reuters
Andrew A. Boccone Independent Director
Age: 68
Bio & Compensation  - Reuters
Arthur M. Dresner Independent Director
Age: 72
Bio & Compensation  - Reuters
Lawrence F. Maietta Independent Director
Age: 56
Bio & Compensation  - Reuters
Christopher W. Nolan Sr. Independent Director
Age: 49
Bio & Compensation  - Reuters